Glucagonoma is a rare and slow-growing pancreatic tumor that usually manifests as glucagonoma syndrome. It is mainly characterized by a typical Dermatosis named necrolytic migratory erythema (NME), Diabetes and glucagon oversecretion. Deep vein thrombosis and Depression complete this set. We report the case of an advanced glucagonoma with liver spread, where all these 4D symptoms occurred but a chronic secretory Diarrhea was the most relevant feature. A 65-year-old man was referred to our center to investigate multiple hepatic nodules evidenced by abdominal tomography. He had a recent diagnosis of diabetes and complained of significant weight loss (25 kg), crusted skin lesions and episodes of a large amount of liquid diarrhea during the past 6 months. On admission, there were erythematous plaques and crusted erosions on his face, back and limbs, plus angular cheilitis and atrophic glossitis. The typical skin manifestation promptly led dermatologists to suspect glucagonoma as the source of our patient’s symptoms. A contrast-enhanced abdominal computed tomography showed a hypervascularized pancreatic lesion and multiple hepatic nodules also hypervascularized in the arterial phase. Despite initial improvement of diarrhea after subcutaneous octreotide, the patient’s impaired nutritional status limited other therapeutic approaches and he died of respiratory failure due to sepsis. His high levels of serum glucagon were not yet available so we performed an autopsy, confirming the diagnosis of metastatic glucagonoma with NME on histology. Chronic diarrhea is not a common feature in glucagonoma syndrome; however, its severity can lead to serious nutritional impairment and set a poor outcome.
Al-FaouriA, AjarmaK, AlghazawiS, Al-RawabdehS, ZayadeenA. Glucagonoma and glucagonoma syndrome: a case report with review of recent advances in management. Case Rep Surg. 2016;2016:1484089. [https://doi.org/10.1155/2016/1484089]. [PMID:26981306]
Lévy-BohbotN, MerleC, GoudetP, et al. Prevalence, characteristics and prognosis of MEN 1-associated glucagonomas, VIPomas, and somatostatinomas: study from the GTE (Groupe des Tumeurs Endocrines) registry. Gastroenterol Clin Biol. 2004;28(11):1075-81. [https://doi.org/10.1016/S0399-8320(04)95184-6]. [PMID:15657529]
TolliverS, GrahamJ, KaffenbergerBH. A review of cutaneous manifestations within glucagonoma syndrome: necrolytic migratory erythema. Int J Dermatol. 2018;57(6):642-5. [https://doi.org/10.1111/ijd.13947]. [PMID:29450880]
ElGuindyYM, JavadiS, MeniasCO, JensenCT, ElsamalotyH, ElsayesKM. Imaging of secretory tumors of the gastrointestinal tract. Abdom Radiol (NY). 2017;42(4):1113-31. [https://doi.org/10.1007/s00261-016-0976-4]. [PMID:27878636]
SongX, ZhengS, YangG, et al. Glucagonoma and the glucagonoma syndrome. Oncol Lett. 2018;15(3):2749-55. [PMID:29435000]
KleinS, JahoorF, BabaH, TownsendCMJr, ShepherdM, WolfeRR. In vivo assessment of the metabolic alterations in glucagonoma syndrome. Metabolism. 1992;41(11):1171-75. [https://doi.org/10.1016/0026-0495(92)90005-U]. [PMID:1435287]
VinikA, PacakK, FelibertiE, PerryRR. Glucagonoma syndrome [Internet]. South Dartmouth: Endotext; 2017 [cited 2019 Jul 24]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK279041/
BarabasM, Huang-DoranI, PitfieldD, et al. Glucagonoma-associated dilated cardiomyopathy refractory to somatostatin analogue therapy. Endocrinol Diabetes Metab Case Rep. 2019;2019(1):EDM180157. [https://doi.org/10.1530/EDM-18-0157]. [PMID:30836327]
WuSL, BaiJ, XuJ, MaQ, WuZ. Necrolytic migratory erythema as the first manifestation of pancreatic neuroendocrine tumor. World J Surg Oncol. 2014;12(1):220. [https://doi.org/10.1186/1477-7819-12-220]. [PMID:25029913]
ZhangP, LiYL, QiuXD, et al. Clinicopathological characteristics and risk factors for recurrence of well-differentiated pancreatic neuroendocrine tumors after radical surgery: a case-control study. World J Surg Oncol. 2019;17(1):66. [https://doi.org/10.1186/s12957-019-1606-8]. [PMID:30975157]
TobererF, HartschuhW, WiedemeyerK. Glucagonoma-associated necrolytic migratory erythema: the broad spectrum of the clinical and histopathological findings and clues to the diagnosis. Am J Dermatopathol. 2019;41(3):e29-32. [https://doi.org/10.1097/DAD.0000000000001219]. [PMID:30124507]
CaplinME, PavelM, RuszniewskiP. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(16):1556-7. [PMID:25317881]
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email